Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1480
Shown on this page
12
Current sort
Recently updated
Campus scope
Massachusetts General Hospital, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Massachusetts General Hospital, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 877–888 of 1,480 matching trials with a site at Massachusetts General Hospital, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1Phase 2 Interventional

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

NCT05443126
Status at this site: Recruiting
View directory record Official record
Conditions
NSCLC
Interventions
EP0031, Platinum chemotherapy, Pemetrexed
Drug
Lead sponsor
Ellipses Pharma
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 5, 2026, 2:41 AM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166
Site status not listed — check the official record
View directory record Official record
Conditions
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
Interventions
Abemaciclib, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
925 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
63
States / cities
Prescott, Arizona • Prescott Valley, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 5, 2026, 2:41 AM EST
Active, not recruiting Phase 3 Interventional

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

NCT03488693
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation, No Radiation
Radiation · Other
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
35 Years and older · Female only
Enrollment
2,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
451
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 349 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 5, 2026, 2:41 AM EST
Active, not recruiting Phase 4 Interventional

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

NCT05003648
Site status not listed — check the official record
View directory record Official record
Conditions
Adrenoleukodystrophy, Restless Legs Syndrome
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 5, 2026, 2:41 AM EST
Active, not recruiting Phase 2 Interventional

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

NCT05774665
Site status not listed — check the official record
View directory record Official record
Conditions
Treatment Resistant Depression, Inflammation, Overweight
Interventions
Omega 3, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 5, 2026, 2:41 AM EST
Recruiting Phase 1 Interventional

A Study of PYX-201 in Advanced Solid Tumors

NCT05720117
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumor, Advanced Solid Tumor
Interventions
PYX-201
Drug
Lead sponsor
Pyxis Oncology, Inc
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
17
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 5, 2026, 2:41 AM EST
Recruiting Phase 1 Interventional

Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

NCT06201416
Status at this site: Recruiting
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SBT777101
Biological
Lead sponsor
Sonoma Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 5, 2026, 2:41 AM EST
Active, not recruiting Phase 2 Interventional Results available

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

NCT03012100
Site status not listed — check the official record
View directory record Official record
Conditions
Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unilateral Breast Carcinoma
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Placebo Administration, Sargramostim
Drug · Other · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • Duarte, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 5, 2026, 2:41 AM EST
Active, not recruiting Phase 2 Interventional

The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer

NCT02653755
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer Radiation
Interventions
Prosigna
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
6
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 5, 2026, 2:41 AM EST
Active, not recruiting Phase 3 Interventional Results available

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

NCT03173248
Site status not listed — check the official record
View directory record Official record
Conditions
Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
Interventions
AG-120, Placebo, Azacitidine
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Louisville, Kentucky • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 5, 2026, 2:41 AM EST
Recruiting Phase 2 Interventional

IVIG for Infection Prevention After CAR-T-Cell Therapy

NCT05952804
Status at this site: Recruiting
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review
Biological · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 5, 2026, 2:41 AM EST
Recruiting Phase 3 Interventional

Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome

NCT06066502
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Respiratory Failure
Interventions
Precision ventilation, Guided usual care ventilation
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
33
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 5, 2026, 2:41 AM EST

About this Massachusetts General Hospital institution page

What this page lists
ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Massachusetts General Hospital at any site, browse by condition, or browse by U.S. city.